Terumo has received the device for evaluation; however, the investigation has yet to be completed.Terumo plans on submitting a follow-up report when the investigation is complete and when more information becomes available.For this reason, terumo references evaluation conclusion code.(b)(4).Results code: results pending completion of evaluation.Conclusions code: conclusion not yet available-evaluation in progress.
|
This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on october 27, 2017.The returned sample was visually inspected.It was confirmed that fx15 units were shipped within a 4 piece fx25rec outer carton.The dhr was reviewed to trace the labeling of the inner and outer cartons.The attached 1 piece and 4 piece label on the manufacturing order (dhr) were correct.Documentation shows appropriate labeling was utilized for packaging before being sent out for sterilization, and released.A definitive root cause could not be determined; however, it is likely that a shipping issue occurred after final release causing product to be removed from the case prior to being delivered to the customer.Review of the labeling and shipping records of the affected products indicates that the product was manufactured several months apart and was shipped directly to a distribution center from the sterilization facility, then the product was shipped to a perfusion service organization prior to shipment to the medical facility.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|